top of page

Everest Medicines' CFO Ian Woo, and an expert in China biotech, describes the company's and the country's evolution from in-licensing assets from the West to developing its own innovative medicines

  • Sep 9, 2025
  • 1 min read

He discusses key assets Everest has in-licensed, including NEFCON and etrasimod, and describes the innovative work Everest is doing in mRNA today. Plus, his thoughts on the efficiency of working in China, and the global dynamics of China-U.S. partnerships in medicine.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page